|
> Early Phase
VaxInnate Corporation is a biotechnology company pioneering breakthrough technology for developing novel and proprietary vaccines. Its technology has the potential to significantly improve the potency, manufacturing capacity, and cost-effectiveness of vaccines. Phase II, open-label, escalating dose ranging study to evaluate the safety and immunogenicity of VaxInnate’s VAX125 influenza vaccine in community-living adults ≥ 65 years of age.
1/ VaxInnate wanted to rapidly deploy a reliable clinical data-collection tool with minimal training requirements.
2/ VaxInnate also needed an intuitive, easy-to-use tool that could unite a total of 18 doctors, nurses and monitors in a collaborative environment.
3/ VaxInnate further required the creation of a complete audit trail for the study that could be available instantly.
• Company Name:
Vaxinnate
• Project:
Phase II, open-label, escalating dose ranging study to evaluate the safety and immunogenicity of VaxInnate’s VAX125 influenza vaccine in community-living adults ≥ 65 years of age.
• Results:
2 months
80 patients included
4 arms of 20 each
3 US sites
• Benefits:
Reliability of data, real-time data to make ongoing critical decisions
Traceability and data security via a secured web portal
Every entry is time-stamped for a precise audit trail
"The business model is win/win for both of us"
|
